Public Funding for Health Innovation North East and North Cumbria Limited

no public description

Globally 1.Globally 1.71 billion people have musculoskeletal symptoms, the leading contributor to disability. Early disease stratification is important to ensure appropriate care (most suited healthcare provider and best treatment choice). Currently the patient journey to diagnosis and effective treatment is long and inefficient, resulting in persistent disease burden and economical loss. This is due to insufficiently understood relations disease causes and similarities in symptoms between diseases, insufficiently distinguishing tests, trial and error approach in initial treatment. SPIDeRR aims to disentangle the real-life complexity of early diagnosis of rheumatic diseases by considering the complete web of factors influencing patients’ symptoms. SPIDeRR’s approach will go well beyond the state-of-the-art in the following ways: - By identifying different disease groups, requiring different therapies, amongst patients with similar symptoms in contrast to the traditional approach aiming to only capture one disease early. - By integrating all relevant data dimensions from every healthcare level (primary and secondary care and patients seeking advice online). - By translating and applying machine learning techniques from the “omics” field to clinical patient data, which will result in new pipelines for translational data science SPIDERR will deliver three clinical models -a symptom checker for patients -a decision support tool for (primary) care providers providing guiding additional examination and referral decisions -a patient-patient similarity network to optimise diagnostic groups in rheumatology and support treatment decision To achieve this we additionally deliver solutions for data integration and shared analyses though GDPR compliant digital research environment and federated learning pipelines. Finally we will test the acceptability of the models through stakeholders studies and provide an implementation scene tailored to current healthcare in Europe

"The Northern Alliance Advanced Therapies Treatment Centre (NAATTC) is a group of NHS hospitals and services. NAATTC has a wide geographical reach across Scotland and the North of England and is responsible for the health care of 15 million NHS patients. Advanced therapies are becoming increasingly available with a growing number of companies developing them both in the UK and worldwide. They are based on the administration of gene- and cell-based products in specialities such as haematology, autoimmunity, hepatology, cardiology and ophthalmology. They are thought to be more effective than existing treatments and provide treatments for diseases where currently no effective therapy exists. However most are still in clinical trials. Advanced therapies present significant challenges to healthcare providers compared with existing treatments. Addressing these challenges in the NHS will require development and dissemination of new skills for nurses, doctors, hospital pharmacists, NHS managers, and commissioners such as NHS England and the clinical commissioning groups (CCGs). It will also require changes in the way treatment is delivered. The changes required in the NHS can only be properly implemented through partnership with the companies that are developing and providing advanced therapies to the NHS. Manufacturers will need assistance with clinical trials to ensure optimal trial design, effective recruitment into clinical trials, and long term follow up of outcomes. The manufacturing and distributing processes are complex and it is critical that these systems are integrated effectively with those within the NHS. The NAATTC already has considerable experience of delivering advanced therapies and clinical trials and will use this experience to work with manufacturers (and their supply chains) to significantly increase their capacity to deliver advanced therapies effectively, safely, and seamlessly to patients within the NHS. It will identify gaps in our existing provision and develop solutions to narrow and eliminate the gaps. It will share the best practice that it develops to other ATTCs and to other NHS organisations. The outcomes will be to deliver these promising therapies to NHS patients and to make the NHS a global leader in their delivery, creating health and wealth for the UK."